INTRODUCTION
Cervical cancer is one of the most prevalent gynecological malignancies in the world [1, 2] . Although major progresses have been made in cancer detection and treatment during the past decades, the 5-year survival rate remains low. Thus, it is important to determine the molecular mechanisms of cervical cancer development, to identify effective prognostic markers and develop novel therapeutic strategies.
Recent studies have uncovered the important role of RNA methylation in cell fate determination, self-renewal and cancer development, indicating a new and promising therapeutic target for investigation [3] . Chemical modified RNA has been demonstrated in recent decades [4] . Among them, the N6-methyladenosine (m 6 A) modification of mRNA/lncRNA is the most prevalent one and plays an important role in gene expression [5, 6] .
The m 6 A methylation is reversible and regulated by adenosine methyltransferases [7] [8] [9] and demethylases [10, 11] . The m 6 A methyltransferases include METTL3 (Methyltransferase like 3), METTL14 (Methyltransferase like 14) , WTAP (Wilms tumor 1-associated protein), RBM15 (RNA binding motif protein 15) and KIAA1429 [7] [8] [9] 12] . And the m 6 A demethylases include FTO (Fat mass and obesity-associated protein) and ALKBH5 (AlkB family member 5) [10, 11, 13] . Furthermore, the m 6 A could be selectively recognized by proteins such as HNRNPC (Heterogeneous nuclear ribonucleoprotein C), HNRNPA2B1 (Heterogeneous nuclear ribonucleoprotein A2/B1), YTHDF2 (YTH N6-methyladenosine RNA binding protein 2), YTHDF1 (YTH N6-methyladenosine RNA binding protein 1) and eIF3 (Eukaryotic initiation factor 3) [5, [14] [15] [16] [17] [18] [19] .
The m 6 A mRNA methylation involves in mRNA splicing, degradation and translation [11, 14, [16] [17] [18] [19] . However, its roles in biological processes have just begun to be uncovered [20] . Previous reports have demonstrated that m 6 A mRNA methylation is implicated in stem cell maintenance and differentiation [21] [22] [23] , and dysregulation of this modification might contribute to development abnormalities, obesity, and other diseases [24, 25] . Recent studies revealed that the m 6 A mRNA methylation also plays an important role in cancer development, such as breast cancer [26, 27] , hematologic malignancies [28, 29] and glioblastoma [30, 31] . However, whether m 6 A mRNA methylation also plays an important role in cervical cancer development remains unknown. Therefore, we investigated the role of m 6 A methylation in cervical cancer in the current study.
RESULTS

Decreased m 6
A level in cervical cancer biopsies A total of 286 cases with cervical cancer were followed. All these patients had received no pre-operation chemotherapy. They were given the same radical operation and underwent the same adjuvant chemotherapy after the surgery. The m 6 A RNA methylation level was firstly analyzed and the data showed that the m 6 A level reduced significantly in cervical cancer tissues comparing with its paired adjacent non-cancerous tissues ( Figure 1A and 1B). Furthermore, the mRNA level of the m 6 A methyltransferases (METTL3 and METTL14) were reduced while the demethylases (FTO and ALKBH5) were increased (Supplementary Figure 1) . The reduced m 6 A level was associated with FIGO stage (P = 0.008), tumor size (P = 0.001), differentiation (P = 0.026), lymph invasion (P = 0.009) and recurrence (P = 0.005, Table 1 ).
During the follow-up for all patients, 52 patients had died and 75 experienced recurrence. Disease-free survival (DFS) and overall survival (OS) was conducted to assess the predictive role of m 6 A level for distant metastasis. Both DFS and OS were significantly higher in the high m 6 A level group than the low m 6 A level group ( Figure  1C ). The low m 6 A level group subsequently developed more recurrence than the high m 6 A level group (P < 0.01, Table 1 ).
It has been demonstrated that the genetic alterations of m 6 A regulators could predict poorer survival in acute myeloid leukemia [29] . Therefore, we also analyzed the gene mutations of m 6 A regulators, including METTL3, METTL14, WTAP, RBM15, KIAA1429, FTO, ALKBH5, HNRNPC, HNRNPA2B1, YTHDF2, YTHDF1 and eIF3 (Supplementary Figure 2) . Mutations in individual genes did not show any significant association with clinicopathological features (data no shown). But when all the mutations were pooled together, the m 6 A regulators mutations showed significantly association with FIGO stage (P = 0.005), tumor size (P = 0.001), differentiation (P = 0.016), lymph invasion (P = 0.002) and recurrence (P = 0.000, Table 2 ). Both DFS and OS were significantly higher in the patients without m6A regulators mutations ( Figure 1D ). Univariate and multivariate analysis showed that patients with reduced m 6 A level or containing gene mutations of m 6 A regulators had a significantly reduced OS and DFS ( Table 3 , Table 4 ).
Taken together, the data showed that the reduced m 6 A level might contribute to cervical cancer development and the poor outcomes.
Reducing m 6
A level promotes cervical cancer cell proliferation
To uncover the important role of m 6 A in cervical cancer development, cell proliferation was analyzed in human cervical cancer cell line SiHa. The m 6 A methylation is regulated by adenosine methyltransferases and demethylases [7] [8] [9] [10] [11] . To reduce the m 6 A level, the adenosine methyltransferases (METTL3 and METTL14) were knocked down through two different shRNA. The knock-down efficiency was evaluated with qPCR ( Figure 2A-2C, Supplementary Figure 3A) . Knocking down both METTL3 and METTL14 promoted SiHa cell proliferation ( Figure 2B, 2D ). On the other hand, overexpressing adenosine demethylases (FTO and ALKBH5) also decreases m 6 A level. The FTO and ALKBH5 overexpression were validated by western blot ( Figure 2E , Supplementary Figure 3B ). And their overexpression significantly promoted cell proliferation ( Figure 2F ). Furthermore, the cell motility was also increased by knocking down METTL3 and METTL14 or overexpressing FTO and ALKBH5 (Supplementary Figure  4) . Thus, reducing m 6 A level could promote cervical cancer cell proliferation, indicating that increasing m 6 A level might have anti-cancer effects in cervical cancer.
Cervical cancer cell proliferation could be suppressed by increasing m6A level
As the reduced m 6 A level was tightly associated with poor outcomes and reducing m 6 A in cervical cancer cell lines could promote cell proliferation, we wondering whether increasing m 6 A would have anti anti-cancer effects or not in cervical cancer. Indeed, increasing m 6 A through knocking down adenosine demethylases (FTO and ALKBH5) or overexpressing adenosine methyltransferases (METTL3 and METTL14) suppressed the cancer cell proliferation ( Figure 3A -3F, Supplementary  Figure 3C-3D) . Furthermore, the cell motility was also decreased by knocking down FTO and ALKBH5 or overexpressing METTL3 and METTL14 (Supplementary Figure 5) . These data demonstrated that increasing m 6 A might inhibit cervical cancer development. of the NOD/SCID mice. Data showed that decreasing m 6 A level promoted cervical cancer development in vivo ( Figure 4A ). On the other hand, knocking-down adenosine demethylases (FTO and ALKBH5) or overexpressing adenosine methyltransferases (METTL3 and METTL14) suppressed cervical cancer development in vivo ( Figure  4B ). Furthermore, when treating the mice with FTO Inhibitor MA2 [32] , the tumor size was significantly reduced (Figure 4C-4E) . These data showed that increasing m 6 A level inhibits cervical cancer development in vivo.
DISCUSSION
Despite the current treatments for cervical cancer having improved the survival significantly, the development of drug resistance still occurs in a great number of patients determining recurrence [1, 2] . Therefore, more efforts should be made to uncover the underlying mechanisms and develop novel therapeutic targets.
In the present study, data showed that the m 6 A level was significantly decreased in cervical cancer tissues comparing with tumor paired normal tissues. Further analysis showed that the reduced m 6 A level tightly associated with cancer progression and poor survival, and could be developed as novel prognostic marker to predict tumor recurrence. Then the m 6 A level was reduced in human cervical cancer cell lines through knocking down the adenosine methyltransferases or overexpressing adenosine demethylases, both of which could promote cell proliferation. On the other hand, increasing m 6 A level suppressed the cancer cell proliferation. The potential therapeutic application of increasing m 6 A was further validated in vivo.
In conclusion, the data showed that cervical cancer cells had very low level of m 6 A. Increasing m 6 A level impeded the cervical cancer development. Therefore, m 6 A might be a potential target for cervical cancer treatment. Table 1 . Samples were collected from the patients consecutively with the standardized protocol. Every patient specimen included two matched pairs, namely, cervical cancer tissues and adjacent normal tissues (≥5 cm away from the tumor). Surgically resected specimens were collected immediately after tumor removal and divided into two aliquots: half were immediately flash-frozen in liquid nitrogen and then frozen at −80°C until RNA and DNA extraction was performed; the remainder was fixed with formalin for histopathological analysis. The diagnosis was confirmed by at least two pathologists. The study was conducted according to the Declaration of Helsinki and approved by the Ethics Committee of Qilu Hospital of Shandong University. Written informed consent was obtained from all patients.
MATERIALS AND METHODS
Patients
RNA extraction and m6A dot blot assay
Total RNA was extracted from tissues with Trizol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. mRNA was prepared from total RNA using the Dynabeads mRNA purification kit (Ambion, catalog no. 61006). RNA samples were quantified using UV spectrophotometry, and equal amounts were mixed 1:1 with glyoxal loading dye (Ambion) and denatured for 20 min at 50°C. 500ng mRNAs were spotted onto a nylon membrane (GE Healthcare). RNA was UV crosslinked to the membrane, and the membranes were blocked for 1 hr in 5% nonfat dry milk in 0.1% PBST (0.1% Tween-20 in 1x PBS, pH 7.4) (Blocking Buffer). Anti-m 6 A antibody (Synaptic Systems; catalog no. 202003) was diluted 1:1000 in 0.1% PBST and incubated on the membranes for 1 hr (25°C) to overnight (4°C). Following extensive washing with 0.1% PBST, HRP-conjugated donkey anti-rabbit IgG (GE Healthcare) was diluted 1:2500 in Blocking Buffer and added to the membranes for 1 hr at 25°C. Membranes were washed again in 0.1% PBST and developed with enhanced chemiluminescence (ECL; GE Healthcare). The intensity of dot blot signal was quantified by ImageJ.
Gene mutation analysis
Genomic DNA was extracted from tissues with QIAamp DNA Blood Mini Kit (Qiagen) according to the manufacturer's instructions. Exons were amplified with high fidelity DNA polymerase (NEB) and sequenced with ABI 3730. Sequence deletion, truncation and missense mutations were characterized as gene mutation in the present study.
Real-time PCR
cDNA was prepared by using the iScript™ cDNA Synthesis kit (Bio-Rad, USA). PCR primers (Generay, Shanghai, China) used for RT-PCR were as follows: for METLL3, sense: 5′-TCCTGACTGACCTTCTTGCTC-3′ and anti-sense: 5′-TCAGCATCGGAA CCAGCAAAG-3′; METLL14, sense: 5′- GTTGGAACA TGGATAGCCGC -3′ and anti-sense: 5′-CAATGCTGTCGGCACTTTCA -3′; FTO, sense: 5′-AACACCAGGCTCTTTACGGTC -3′ and anti-sense: 5′-TGTCCGTTGTAGGATGAACCC -3′; ALKBH5, sense: 5′- ATGCACCCCGGTTGGAAAC -3′ and antisense: 5′- GACTTGCGCCAGTAGTTCTCA-3′;β-actin, sense: 5′-CCTGACTGACTACCTCATGAAG-3′ and antisense: 5′-GACGTAGCACAGCTTCTCCTTA-3′. RT-PCR amplification reaction was prepared with the SYBR Green PCR kit (Bio-rad, USA) and performed using the 7500 fast Real-Time PCR system (Applied Biosystems, USA). PCR products were verified by melting curve analysis. Relative mRNA levels of target genes were calculated by the 2 -ΔΔct method.
Western blotting
Total protein from cultured cells were lysed in RIPA buffer with protease inhibitor (Beyotime, Shanghai, China). The protein was quantified using a BCA assay kit (Beyotime, Shanghai, China). A total of 20 μg of total protein were separated by 10% SDS-PAGE, transferred onto polyvinylidene fluoride membranes, and then reacted with primary antibodies against METLL3, METLL14, FTO, ALKBH5 and β-actin (all from Abcam, Cambridge, UK). After being extensively washed with PBS containing 0.1 % Triton X-100, the membranes were incubated with alkaline phosphatase-conjugated goat anti-rabbit antibody for 30 min at room temperature. The bands were visualized using 1-step TM NBT/BCIP reagents (Thermo Fisher Scientific, Rockford, IL, USA) and detected by an Alpha Imager (Alpha Innotech, San Leandro, CA, USA).
Cell culture
The cervical cancer cell lines SiHa was obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA) and cultured in DMEM (GIBCO, Shanghai, China) supplemented with 10 % FBS.
Plasmid DNA and virus preparation
shRNAs were cloned into lentiviral pLKO.1-puro vector. The following shRNA sequences were used: control shRNA, 5`-ACTCAAAAGGAAGTG ACAAGA-30; METTL3
shRNA-1, 50-GCTGCACTTCAGACG AATT-30; METTL3 shRNA-2, 5`-CCACCTCAGTGGATC TGTT-3`; METTL14 shRNA-1, 5`-GCTAAAGGATGAG TTAAT-3`; METTL14 shRNA-2, 5`-GGACTTGGGATG ATATTAT-3`; FTO shRNA-1, 5`-GGAAGATTTAAACT CCATGAAG-3`; FTO shRNA-2, 5`-CAAAGTGTTCAA TGGATGCAAC-3`; ALKBH5 shRNA-1, 5`-AGGTTCTC ATATTCTTGGTATC-3`; ALKBH5 shRNA-2, 5`-GATGAAATCACTCACTGCATAC-3`. The METTL3, METTL14, FTO and ALKBH5 expressing lentiviral vector was prepared by cloning the human full coding sequences into the pLVX-puro lentiviral vector.
Lentiviruses were prepared using 293T cells according to the manufacturer's instructions. Cells were incubated with lentivirus and 4 mg/mL polybrene (AmericanBio) for 24 hr.
Cell growth assay
Cells were seeded at 5x10 4 cells per well in 24-well plates and cultured for 3 days. Cell number was counted using a hemocytometer.
Animal study [6] [7] [8] weeks old NOD/SCID mice (Charles River Laboratories, Beijing, China) were housed in specific pathogen-free conditions. The study was approved by the Research Ethics Committee of Shandong University. Mice were housed in the pathogen free region and monitored daily during the experiments and the mice would be sacrificed when the weight loss is more than 20%. For evaluation of the tumor growth in vivo, 5 × 10 6 cells were suspended in 200 μl PBS and injected subcutaneously into the dorsal scapula region of the mice. For FTO Inhibitor MA2 treatment, the mice were treated with MA2 (5 nmol in 100μL PBS) or vehicle control by intratumoral injection once a week for 4 weeks. Tumor size was measured with fine digital calipers and calculated by the following formula: tumor volume =0.5 × width 2 × length. For imaging the tumor clearance in vivo, cells were transduced with a lentiviral construct that drives the expression of the click beetle red luciferase (CBR). Bioluminescence imaging was performed 4 weeks after injection. For imaging, mice were injected i.p. with D-luciferin (150 μg/g body weight), anesthetized (2% isoflurane), and placed in an IVIS 50 imaging system (Xenogen). Regions of interest (ROI) were defined manually over the whole body with Living-Image software (Igor Wavemetrics) for determining tumor burden signal intensities.
Statistical analysis
Data were expressed as mean (±SE) and analyzed by a SPSS software package (SPSS Standard version 13.0, SPSS Inc, USA). Differences between variables were assessed by the Chi-square test. Survival analysis of patients with cervical cancer was calculated by KaplanMeier analysis. A log rank test was used to compare different survival curves. A Cox proportional hazards model was used to calculate univariate and multivariate hazard ratios for the variables. Unpaired Student's t test and one way ANOVA were used as appropriate to assess the statistical significant of difference. P values under 0.05 were considered statistically significant.
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